ECSP22093029A - Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf - Google Patents

Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf

Info

Publication number
ECSP22093029A
ECSP22093029A ECSENADI202293029A ECDI202293029A ECSP22093029A EC SP22093029 A ECSP22093029 A EC SP22093029A EC SENADI202293029 A ECSENADI202293029 A EC SENADI202293029A EC DI202293029 A ECDI202293029 A EC DI202293029A EC SP22093029 A ECSP22093029 A EC SP22093029A
Authority
EC
Ecuador
Prior art keywords
braf
treatment
diseases
dihydroquinazolinone
oxo
Prior art date
Application number
ECSENADI202293029A
Other languages
English (en)
Inventor
Tanna Marie Bettendorf
Dean Russell Kahn
Barbour Patrick Michael Doerner
Li Ren
David Austin Moreno
Alex Andrew Kellum
Ellen Ruth Laird
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of ECSP22093029A publication Critical patent/ECSP22093029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Se proporciona en la presente un compuesto de la Fórmula I: [IMAGEN ADJUNTA] o una sal aceptable desde el punto de vista farmacéutico de este, en donde R1, R2, R3, R4, R5, R6, R7 y L son como se definen en la presente, para el tratamiento de enfermedades y trastornos asociados a BRAF, incluso tumores asociados a BRAF.
ECSENADI202293029A 2020-06-09 2022-12-07 Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf ECSP22093029A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036522P 2020-06-09 2020-06-09
US202063116204P 2020-11-20 2020-11-20
US202163175655P 2021-04-16 2021-04-16

Publications (1)

Publication Number Publication Date
ECSP22093029A true ECSP22093029A (es) 2023-02-28

Family

ID=76355554

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202293029A ECSP22093029A (es) 2020-06-09 2022-12-07 Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf

Country Status (18)

Country Link
US (1) US20220288074A1 (es)
EP (1) EP4161907A1 (es)
JP (2) JP7312335B2 (es)
KR (1) KR20230019944A (es)
CN (1) CN116096710A (es)
AU (1) AU2021289163A1 (es)
BR (1) BR112022024597A2 (es)
CA (1) CA3186343A1 (es)
CL (1) CL2022003326A1 (es)
CO (1) CO2022017876A2 (es)
CR (1) CR20220626A (es)
DO (1) DOP2022000282A (es)
EC (1) ECSP22093029A (es)
IL (1) IL298300A (es)
MX (1) MX2022015703A (es)
PE (1) PE20231651A1 (es)
UY (1) UY39261A (es)
WO (1) WO2021250521A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2023105371A1 (en) * 2021-12-08 2023-06-15 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
WO2023178284A1 (en) * 2022-03-17 2023-09-21 St. Jude Children’S Research Hospital Treatment of low-grade glioma with mirdametinib
WO2023183470A1 (en) * 2022-03-24 2023-09-28 Vibliome Therapeutics, Llc Modulators of protein kinases
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130536B1 (en) 2002-03-13 2013-05-08 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0610139A2 (pt) 2005-05-18 2010-06-01 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de uso dos mesmos
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
US11661075B2 (en) 2018-09-11 2023-05-30 NetraDyne, Inc. Inward/outward vehicle monitoring for remote reporting and in-cab warning enhancements
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
JP2023524910A (ja) 2023-06-13
US20220288074A1 (en) 2022-09-15
BR112022024597A2 (pt) 2022-12-27
IL298300A (en) 2023-01-01
JP7312335B2 (ja) 2023-07-20
EP4161907A1 (en) 2023-04-12
KR20230019944A (ko) 2023-02-09
JP2023123854A (ja) 2023-09-05
TW202214577A (zh) 2022-04-16
DOP2022000282A (es) 2023-03-31
MX2022015703A (es) 2023-01-24
CN116096710A (zh) 2023-05-09
PE20231651A1 (es) 2023-10-17
WO2021250521A1 (en) 2021-12-16
CA3186343A1 (en) 2021-12-16
UY39261A (es) 2022-01-31
AU2021289163A1 (en) 2022-12-22
CL2022003326A1 (es) 2023-02-24
CO2022017876A2 (es) 2022-12-20
CR20220626A (es) 2023-01-23

Similar Documents

Publication Publication Date Title
ECSP22093029A (es) Compuestos de 4-oxo-3,4-dihidroquinazolinona para el tratamiento de enfermedades y trastornos asociados a braf
CO2022008091A2 (es) Inhibidores de kras g12c
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
PE20211089A1 (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
AR116604A1 (es) Inhibidores de kras g12c
CY1118026T1 (el) Ρυθμιστης υποδοχεα ανδρογονων για τη θεραπευτικη αντιμετωπιση του καρκινου του προστατη και νοσων σχετιζομενων με υποδοχεα ανδρογονων
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
NI201300111A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CO2021017438A2 (es) Derivados de quinazolin-4-ona útiles en el tratamiento de enfermedades y trastornos asociadas con braf
SG176628A1 (en) Aminopyrrolidinone derivatives and uses thereof
JP2015504091A5 (es)
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
PE20220710A1 (es) Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl)
ECSP19020742A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
CL2021000731A1 (es) Derivados de indano para uso en el tratamiento de infección bacteriana